Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348128 | 0.87 | NLRP3 (0.46) | NLRP3MAPTTP53SMN1; SMN2TSHR | |
| SCHEMBL29348127 | 0.87 | NLRP3 (0.46) | NLRP3AKR1B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL24077213 | 0.86 | NLRP3 (0.60) | NLRP3AKR1B1MAPTGPR139 | |
| SCHEMBL30168573 | 0.86 | NLRP3 (0.60) | NLRP3AKR1B1MAPTGPR139 | |
| SCHEMBL29348102 | 0.85 | NLRP3 (0.49) | NLRP3AKR1B1MAPTTP53 | |
| SCHEMBL24076362 | 0.85 | NLRP3 (0.46) | NLRP3AKR1B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL24834599 | 0.84 | NLRP3 (0.42) | NLRP3AKR1B1SMN1; SMN2TSHRHTT | |
| SCHEMBL29348106 | 0.83 | NLRP3 (0.47) | NLRP3AKR1B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL24834601 | 0.82 | NLRP3 (0.41) | NLRP3AKR1B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL24077227 | 0.81 | NLRP3 (0.55) | NLRP3AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4567028-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2025-06-11 | — | — | EP | disclosed |
| EP-4330235-B1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-12 | — | — | EP | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| EP-4330235-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022229315-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885AKR1B1 320/4885MAPT 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.